NasdaqGS - Delayed Quote USD

Indivior PLC (INDV)

Compare
11.90
-0.30
(-2.46%)
At close: January 31 at 4:00:02 PM EST
11.90
0.00
(0.00%)
After hours: January 31 at 5:25:03 PM EST
Loading Chart for INDV
DELL
  • Previous Close 12.20
  • Open 12.17
  • Bid 8.72 x 200
  • Ask 15.19 x 200
  • Day's Range 11.76 - 12.17
  • 52 Week Range 7.33 - 23.22
  • Volume 830,064
  • Avg. Volume 1,222,305
  • Market Cap (intraday) 1.516B
  • Beta (5Y Monthly) 0.27
  • PE Ratio (TTM) --
  • EPS (TTM) -0.03
  • Earnings Date Feb 20, 2025 - Feb 24, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date Jun 16, 2016
  • 1y Target Est 16.00

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

www.indivior.com

1,000

Full Time Employees

December 31

Fiscal Year Ends

Recent News: INDV

View More

Performance Overview: INDV

Trailing total returns as of 1/31/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

INDV
2.30%
FTSE 100
6.81%

1-Year Return

INDV
32.42%
FTSE 100
13.14%

3-Year Return

INDV
296.67%
FTSE 100
16.18%

5-Year Return

INDV
2,233.33%
FTSE 100
17.50%

Compare To: INDV

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: INDV

View More

Valuation Measures

Annual
As of 1/31/2025
  • Market Cap

    1.48B

  • Enterprise Value

    1.44B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.38

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    1.22

  • Enterprise Value/EBITDA

    25.33

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -0.25%

  • Return on Assets (ttm)

    11.27%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    1.18B

  • Net Income Avi to Common (ttm)

    -3M

  • Diluted EPS (ttm)

    -0.03

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    318M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -70.88M

Research Analysis: INDV

View More

Company Insights: INDV

Research Reports: INDV

View More

People Also Watch

Waiting for permission
Allow microphone access to enable voice search

Try again.